Very Low Prevalence of Vaccine Human Papillomavirus Types among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination

Journal of Infectious Diseases

Volumn 217, Issue 10, 2018, Pages 1590-1600

  Machalek, Dorothy A ^a,b,c   Garland, Suzanne M ^b,c   Brotherton, Julia M L ^c,d   Bateson, Deborah ^e,f   McNamee, Kathleen ^g,h   Stewart, Mary ^e   Rachel Skinner, S ^f   Liu, Bette ⁱ   Cornall, Alyssa M ^a,b,c   Kaldor, John M ^j   Tabrizi, Sepehr N ^a,b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN CYTOLOGY SERVICE   (Australia)

^e New South Wales Department of Planning and Infrastructure   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Family Planning Victoria   (Australia)

^h MONASH UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

HPV infection; human papillomavirus; prevalence; surveillance; vaccine impact; women

Indexed keywords

WART VIRUS VACCINE;

ADULT; AUSTRALIA; AUSTRALIAN; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CYTOLOGY; VACCINATION; ADOLESCENT; IMMUNOLOGY; PAPILLOMAVIRIDAE; PREVENTIVE HEALTH SERVICE; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; VACCINATION; YOUNG ADULT;

EID: 85046248089     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy075     Document Type: Conference Paper

References (44)

1. de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450-61.
2. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5):F12-23.
3. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011; 11:13.
4. Brotherton JM, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014; 32:592-7.
5. Brotherton JM, Murray SL, Hall MA, et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 2013; 199:614-7.
6. Brotherton JM, Winch KL, Bicknell L, Chappell G, Saville M. HPV vaccine coverage is increasing in Australia. Med J Aust 2017; 206:262.
7. Chow EP, Danielewski JA, Fehler G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 2015; 15:1314-23.
8. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458.
9. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227.
10. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
11. Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust 2016; 204:184-184e1.
12. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032.
13. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14:958-66.
14. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51.
15. Brotherton JM, Condon JR, McIntyre PB, et al. Human papillomavirus prevalence to age 60 years among Australian women prevaccination. Sex Health 2015; 12:353-9.
16. Garland SM, Brotherton JM, Condon JR, et al.; WHINURS study group. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011; 9:104.
17. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011; 8:171-8.
18. Martinez SB, Palomares JC, Artura A, et al. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J Virol Methods 2012; 180:7-10.
19. Phillips S, Cornall AM, Machalek DA, et al. Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus. Eur J Clin Microbiol Infect Dis 2016; 35:1305-7.
20. Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006; 44:2428-33.
21. Resnick RM, Cornelissen MT, Wright DK, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990; 82:1477-84.
22. Tabrizi SN, Stevens M, Chen S, Rudland E, Kornegay JR, Garland SM. Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol 2005; 123:896-9.
23. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61.
24. Layton-Henry J, Scurry J, Planner R, et al. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996; 6:193-9.
25. Tabrizi SN, Brotherton JM, Stevens MP, et al. HPV genotyping prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. J Clin Virol 2014; 60:250-6.
26. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008; 147:290-6.
27. Joura EA, Giuliano AR, Iversen OE, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
28. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015; 211:91-9.
29. Castellsague X, Munoz N, Pitisuttithum P, et al. End-ofstudy safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011; 105:28-37.
30. Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Res 2015; 1(Suppl C): 59-73.
31. Lamb F, Herweijer E, Ploner A, et al. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open 2017; 7:e015021.
32. Sankaranarayanan R, Prabhu PR, Pawlita M, et al.; Indian HPV Vaccine Study Group. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2016; 17:67-77.
33. Brisson M, Benard E, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1:e8-e17.
34. National HPV Vaccination Program Register. National (Australia) HPV three-dose vaccine coverage for adolescents turning 15 years of age. http://www.hpvregister.org. au/research/coverage-data. Accessed 21 November 2017.
35. Prime Minister of Australia. Announcement of the addition of Gardasil-9 to the national immunisation program. https://www.pm.gov.au/media/2017-10-08/announcement-addition-gardasil-9-national-immunisation-program. Accessed 2 November 2017.
36. Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 2009; 83:1443-55.
37. Tota JE, Struyf F, Merikukka M, et al. Evaluation of type replacement following HPV16/18 vaccination: pooled analysis of two randomized trials. J Natl Cancer Inst 2017; 109:djw300.
38. Tota JE, Ramanakumar AV, Villa LL, et al. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol Biomarkers Prev 2015; 24:286-90.
39. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-16.
40. Ding L, Widdice LE, Kahn JA. Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction. Vaccine 2017; 35:7217-21.
41. Greenhalgh EM, Bayly M, Winstanley MH. 1.4 Prevalence of smoking-young adults. In: Scollo MM, Winstanley MH, eds. Tobacco in Australia: Facts and issues. Melbourne: Cancer Council Victoria; 2015. http://www.tobaccoinaustralia. org.au/chapter-1-prevalence/1-4-prevalence-ofsmoking-young-adults. Accessed 2 November 2017.
42. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med 2017; 14:e1002388.
43. Osborne SL, Tabrizi SN, Brotherton JM, et al.; VACCINE Study Group. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 2015; 33:201-8.
44. Mesher D, Soldan K, Lehtinen M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 2016; 22:1732-40.